DYAI - Dyadic International, Inc.
| Previous Close | 4.93 |
| Open | 4.93 |
| Bid | 4.87 x 800 |
| Ask | 5.24 x 1400 |
| Day's Range | 4.85 - 5.29 |
| 52 Week Range | 2.51 - 8.00 |
| Volume | 185,037 |
| Avg. Volume | 273,293 |
| Market Cap | 138.438M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.31 |
| Earnings Date | May 06, 2020 - May 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.50 |
- Thomson Reuters StreetEvents
Edited Transcript of DYAI earnings conference call or presentation 30-Mar-20 9:00pm GMT
Q4 2019 Dyadic International Inc Earnings Call
- ACCESSWIRE
Dyadic Reports 2019 Year End Results and Recent Developments
New research license agreement with WuXi Biologics, a leading global CDMO Two new fully funded collaborations and one expanded collaboration signed in 2020, including the t hird fully funded collaboration ...
- ACCESSWIRE
Dyadic International, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. (NASDAQ:DYAI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at ...
- ACCESSWIRE
Dyadic Announces Nonexclusive Research License with WuXi Biologics
JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it has entered into a nonexclusive research collaboration with WuXi Biologics, a leading global open-access biologics technology platform company and Contract Development and Manufacturing Organization (CDMO). Under the terms of the research license agreement, Dyadic will grant WuXi Biologics restricted access to its proprietary and patented C1 gene expression platform and allow WuXi Biologics to evaluate the C1 technology in a cGMP facility and to perform certain experiments to the C1 cell lines for any other internal noncommercial purpose.
- ACCESSWIRE
Dyadic International, Inc. to Present at the New York City based Investor Summit on March 25th-26th
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic's Chief Financial Officer Ping Rawson will be presenting at this year's New York City based Investor Summit ...
- ACCESSWIRE
Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress
JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its management participated in the ROTH Virtual Conference on Tuesday, March 17, 2020. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.
- ACCESSWIRE
Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020
JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for year ended December 31, 2019 after the market close on Monday, March 30, 2020 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales.
- Simply Wall St.
Dyadic International's (NASDAQ:DYAI) Wonderful 462% Share Price Increase Shows How Capitalism Can Build Wealth
Buying shares in the best businesses can build meaningful wealth for you and your family. While the best companies are...
- Yahoo Finance
Coronavirus update: Trump taps Pence to lead coronavirus response; first case in CA with no travel link
Europe’s attempts to contain its escalating coronavirus outbreak appeared to be faltering, as Germany became the latest country to warn that it was on the verge of an epidemic.
- ACCESSWIRE
Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases
NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research ("IIBR"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats. IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).
- ACCESSWIRE
Dyadic Announces New Milestone as G2 Human Like Glycosylation Reached
JUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the 15th European Conference on Fungal Genetics ("ECFG15") demonstrated that its C1 strain has been glyco-engineered to achieve a core human like G2 glycan level over 76% on Host Cell Proteins (HCP). The G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd ("VTT") at the ECFG15 conference in Rome, Italy on Wednesday, February 19. "Our collaboration with Dyadic continues to achieve new scientific milestones regarding glycoengineering Dyadic's C1 industrially proven cell line, building upon the 95% core human G0 glycosylation milestone that was reported by Markku Saloheimo, Ph.D., Senior Principal Scientist at VTT, during the PEGS Europe (Protein & Antibody Engineering Summit) in November 2019," said Anne Huuskonen, VTT Senior Scientist.
- ACCESSWIRE
Dyadic to Present at Two Upcoming Conferences
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.
- ACCESSWIRE
Dyadic to Interview with Bloomberg TV on Friday, January 31, 2020
JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying ...
- MarketWatch
Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.
- ACCESSWIRE
Dyadic Interviewed with FOX Business Network
JUPITER, FL / ACCESSWIRE / January 28, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb, was interviewed by Liz Claman "The Claman Countdown" from FOX Business Network on Monday, January 27, 2020. Liz Claman joined FOX Business Network (FBN) as an anchor in October 2007.
- MarketWatch
CDC officials say coronavirus is similar to SARS, no new U.S. cases reported
At least 110 people in 26 states have been identified as persons under investigation for coronavirus, Centers for Disease Control and Prevention officials said Monday.
- ACCESSWIRE
Dyadic to Interview with FOX Business Network on Monday, January 27, 2020
JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying ...
- Zacks Small Cap Research
DYAI: Dyadic’s Fourth Quarter Operational Update
By John Vandermosten, CFA NASDAQ:DYAI In a press release issued earlier this week Dyadic International Inc. (NASDAQ:DYAI) provided an update on achievements during the fourth quarter 2019. The summary was provided prior to meetings and presentations at conferences over the next week. Dyadic announced yet another agreement with a big pharma company which will be the second top 10 pharma partner
- ACCESSWIRE
Dyadic Reports Continued Positive Business Trends and Scientific Results in Fourth Quarter 2019
JUPITER, FL / ACCESSWIRE / January 6, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today provided an update on its recent business developments and scientific results in the fourth quarter of 2019.
- Simply Wall St.
Is Dyadic International, Inc. (NASDAQ:DYAI) Excessively Paying Its CEO?
In 2004 Mark Emalfarb was appointed CEO of Dyadic International, Inc. (NASDAQ:DYAI). First, this article will compare...
- Zacks Small Cap Research
DYAI: Glycosylation Milestone Opens Doors For mAb Production
By John Vandermosten, CFA NASDAQ::DYAI Dyadic (NASDAQ:DYAI) achieved an impressive milestone in its glycoengineering efforts which was announced via VTT’s 1 presentation at the Protein and Antibody Engineering Summit (PEGS) Europe in Lisbon a few weeks ago. The event was memorialized in a press release on November 25th. It announced that Dyadic’s filamentous fungi expression system Myceliophthora
- Insider Monkey
Is Dyadic International, Inc. (DYAI) A Good Stock To Buy?
Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]
- ACCESSWIRE
Dyadic Announces Achieving Human Like Glycan Structures From Its Engineered C1 Cell Line
JUPITER, FL / ACCESSWIRE / November 25, 2019 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the annual PEGS Europe Protein & Antibody Engineering Summit demonstrated that its C1 strain has been successfully glyco-engineered to impart the core human like G0 glycan structure at high levels. The G0 glycosylation data was presented by Markku Saloheimo, Ph.D., from the VTT Technical Research Centre of Finland Ltd ("VTT") at the conference in Lisbon, Portugal on Thursday, November 21.
- Zacks Small Cap Research
DYAI: Third Quarter 2019 Financial & Operational Results
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released third quarter 2019 financial and operational results on November 13, 2019. Revenues were $0.5 million and represented research and development proceeds from partners working to develop C1. Total expenses were $2.4 million and net loss was ($1.7) million after adding interest
- ACCESSWIRE
Dyadic Reports Third Quarter 2019 Results And Recent Developments
New Fully Funded Research Collaboration with Leading Animal Health Company; Fifth Partnership in Animal Sector Expansion of Existing Research Collaboration to Express an Additional Protein with Major Animal ...
